85 related articles for article (PubMed ID: 29744867)
1. P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib.
Li W; Sparidans RW; Wang Y; Lebre MC; Wagenaar E; Beijnen JH; Schinkel AH
Int J Cancer; 2018 Oct; 143(8):2029-2038. PubMed ID: 29744867
[TBL] [Abstract][Full Text] [Related]
2. ABCB1 attenuates brain exposure to the KRAS
Rijmers J; Retmana IA; Bui V; Arguedas D; Lebre MC; Sparidans RW; Beijnen JH; Schinkel AH
Biomed Pharmacother; 2024 Jun; 175():116720. PubMed ID: 38733773
[TBL] [Abstract][Full Text] [Related]
3. Coadministration of ABCB1/P-glycoprotein inhibitor elacridar improves tissue distribution of ritonavir-boosted oral cabazitaxel in mice.
Loos NHC; Martins MLF; de Jong D; Lebre MC; Tibben M; Beijnen JH; Schinkel AH
Int J Pharm; 2024 Jan; 650():123708. PubMed ID: 38135258
[TBL] [Abstract][Full Text] [Related]
4. The ABCB1 and ABCG2 efflux transporters limit brain disposition of the SYK inhibitors entospletinib and lanraplenib.
Loos NHC; Sparidans RW; Heydari P; Bui V; Lebre MC; Beijnen JH; Schinkel AH
Toxicol Appl Pharmacol; 2024 Apr; 485():116911. PubMed ID: 38527694
[TBL] [Abstract][Full Text] [Related]
5. P-gp/ABCB1 exerts differential impacts on brain and fetal exposure to norbuprenorphine.
Liao MZ; Gao C; Shireman LM; Phillips B; Risler LJ; Neradugomma NK; Choudhari P; Prasad B; Shen DD; Mao Q
Pharmacol Res; 2017 May; 119():61-71. PubMed ID: 28111265
[TBL] [Abstract][Full Text] [Related]
6. Interplay of OATP1A/1B/2B1 uptake transporters and ABCB1 and ABCG2 efflux transporters in the handling of bilirubin and drugs.
Li W; Sparidans RW; Wang Y; Martins MLF; de Waart DR; van Tellingen O; Song JY; Lebre MC; van Hoppe S; Wagenaar E; Beijnen JH; Schinkel AH
Biomed Pharmacother; 2024 Jun; 175():116644. PubMed ID: 38692057
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer.
Chen J; Bearz A; Kim DW; Mamdani H; Bauman J; Chiari R; Ou SI; Solomon BJ; Soo RA; Felip E; Shaw AT; Thurm H; Clancy JS; Lee K; O'Gorman M; Tanski C; Pithavala YK
Clin Pharmacokinet; 2024 Feb; 63(2):171-182. PubMed ID: 38079095
[TBL] [Abstract][Full Text] [Related]
8. Second-trimester medical abortion after exposure to lorlatinib during early pregnancy, a case report.
Mawet M; Basse C; Barrois M; Gligorov J; Cadranel J; Chabbert-Buffet N; Selleret L
J Gynecol Obstet Hum Reprod; 2023 Dec; 52(10):102673. PubMed ID: 37777070
[TBL] [Abstract][Full Text] [Related]
9. In-depth Analysis of Lorlatinib-related neurocognitive Adverse Events in Patients With Non-small-cell Lung Cancer.
Schoenmaekers J; Dijkstra J; van der Wekken A; Paats M; Broen M; Brandts L; Dingemans AM; Hendriks L
Clin Lung Cancer; 2024 Mar; 25(2):168-174.e1. PubMed ID: 38151408
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of quinacrine efflux from mouse brain via the P-glycoprotein efflux transporter.
Ahn M; Ghaemmaghami S; Huang Y; Phuan PW; May BC; Giles K; DeArmond SJ; Prusiner SB
PLoS One; 2012; 7(7):e39112. PubMed ID: 22768295
[TBL] [Abstract][Full Text] [Related]
11. Tazemetostat synergistically combats multidrug resistance by the unique triple inhibition of ABCB1, ABCC1, and ABCG2 efflux transporters in vitro and ex vivo.
Budagaga Y; Sabet Z; Zhang Y; Novotná E; Hanke I; Rozkoš T; Hofman J
Biochem Pharmacol; 2023 Oct; 216():115769. PubMed ID: 37634597
[TBL] [Abstract][Full Text] [Related]
12. Bilateral optic neuropathy associated with lorlatinib monotherapy for ALK-positive metastatic lung adenocarcinoma.
Kong AW; Engelmann AR; Hosseini M; Bonelli L
Am J Ophthalmol Case Rep; 2024 Jun; 34():102063. PubMed ID: 38707952
[TBL] [Abstract][Full Text] [Related]
13. Humanization of the Blood-Brain Barrier Transporter ABCB1 in Mice Disrupts Genomic Locus - Lessons from Three Unsuccessful Approaches.
Krohn M; Wanek T; Menet MC; Noack A; Declèves X; Langer O; Löscher W; Pahnke J
Eur J Microbiol Immunol (Bp); 2018 Sep; 8(3):78-86. PubMed ID: 30345087
[TBL] [Abstract][Full Text] [Related]
14. ALK inhibitors suppress HCC and synergize with anti-PD-1 therapy and ABT-263 in preclinical models.
Bugide S; Reddy DS; Malvi P; Gupta R; Wajapeyee N
iScience; 2024 May; 27(5):109800. PubMed ID: 38741708
[TBL] [Abstract][Full Text] [Related]
15. Differential network analysis of ROS1 inhibitors reveals lorlatinib polypharmacology through co-targeting PYK2.
Liao Y; Remsing Rix LL; Li X; Fang B; Izumi V; Welsh EA; Monastyrskyi A; Haura EB; Koomen JM; Doebele RC; Rix U
Cell Chem Biol; 2024 Feb; 31(2):284-297.e10. PubMed ID: 37848034
[TBL] [Abstract][Full Text] [Related]
16. A case study on severe psychiatric symptoms induced by lorlatinib.
Liu MA; Xu E; Shu CA
Psychooncology; 2024 Jan; 33(1):e6283. PubMed ID: 38282214
[No Abstract] [Full Text] [Related]
17. Lorlatinib in ALK- and ROS1-positive NSCLC: the future has a start.
Facchinetti F; Friboulet L
Transl Lung Cancer Res; 2018 Apr; 7(Suppl 2):S103-S106. PubMed ID: 29782561
[No Abstract] [Full Text] [Related]
18. Lorlatinib Treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven Cancer.
Redaelli S; Ceccon M; Zappa M; Sharma GG; Mastini C; Mauri M; Nigoghossian M; Massimino L; Cordani N; Farina F; Piazza R; Gambacorti-Passerini C; Mologni L
Cancer Res; 2018 Dec; 78(24):6866-6880. PubMed ID: 30322862
[TBL] [Abstract][Full Text] [Related]
19. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]